Levy Lauds Biomarker-Driven Data in Lung Cancer

Season 4 Episode 39  ·  Mar 11, 2021, 09:08 PM

Headliner
Share
Subscribe

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

Share
Subscribe
Next
Spira Spotlights Sotorasib and Targeting KRAS Mutations in NSCLC
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air